Valeant Finalizes Sale of Skin Treatment Drugs to Nestle
Swiss food giant Nestle announced today that it has completed its acquisition of Valeant Pharmaceuticals' commercialization rights to several key injectable aesthetic dermatology products in the U.S. and Canada.
The $1.4 billion deal, which included corrective facial aesthetic treatments Restylane, Perlane, Emervel and Dysport, was announced on May 28 but needed approval from regulators to be complete.
The products are already manufactured by Nestle's Galderma medical unit, so the deal will transfer the North American distribution rights from Valeant to Nestle.
Read the Business Standard press release